http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
조시현,최재성,이정호 국방기술품질원 2022 국방품질연구논집 Vol.4 No.2
본 논문은 유도탄 추진기관의 지상연소시험 간 계측된 연소관 내부 압력과 소음에 대한 특성을 분석한 논문이다. 추진기관은 유도탄을 목표물에 도달할 수 있게 하는 구성품으로 내탄도 성능 분석을 위해선 지상연소시험이 필수적이다. 시험 간 연소관 내부 연소 이상 현상 등을 분석하기 위해 연소관 내부 압력 측정이 필요하며, 추진기관 연소를 위한 추진제 점화 시 강한 충격소음이 발생한다. 본 시험은 추진기관 2종의 지상연소시험 간 총 4회에 걸쳐 압력 및 소음을 게측하였으며, 동일 추진기관에서 연소관 내부 압력 변화에 따른 소음 변화량을 확인한 결과 연소초기에 최대압력에 따라 최대음압 수준이 결정된다고 판단하였다. 이를 통해 연소 초기 최대압력과 최대 음압과의 선형 Fitting을 통한 경향성을 분석하였고, Pearson's r값이 1에 가깝게 나타남을 확인하였다. 또한, 서로 다른 추진기관의 지상연소시험 간 연소관 내부 최대압력과 같은 거리에서 계측된 음압의 비교,분석을 통해 추진기관 노즐의 출구 직경과 연소가스 확산각에 따라 연소 초기 압력이 낮음에도 불구하고 최대 음압이 높게 형성됨을 확인하였다.
조시현,신호,김종기 대한신경외과학회 1982 Journal of Korean neurosurgical society Vol.11 No.2
Between February-1, 1977 and August-31, 1981, 46 patients underwent anterior cervical discectomy without interbody fusion for the treatment of the cervical disc protrusion. Of these patients, 40 patients who were followed up for more than 6 months after surgery were analyzed. 1. 87.5% of patients had good or excellent clinical results(93.3% in soft disc patients and 84% in hard disc patients) 2. 92.5% of patients revealed good or excellent alignment of the cervical spine and none were worsen. 3. The incidence of anatomical fusion was 20% by a year and 30% by 1½ years. Comparing with the anterior interbody fusion, the simple discectomy is technically simpler and shows similar clinical results.
The effect of levonorgestrel releasing intrauterine device on lymphangiogenesis of adenomyosis
조시현,전영은,정지안,서석교,최영식,이병석 대한산부인과학회 2012 대한산부인과학회 학술대회 Vol.98 No.-
Adenomyosis defined by the presence of endometrial mucosa within the myometrium and often associated with heavy menstrual bleeding and dysmenorrhea. Although, it has been shown that levonorgestrel releasing intrauterine device (LNG-IUD) can effectively treat adenomyosis related symptoms, the exact mechanism has not been fully understood yet. Under the assumption that lymphangiogenesis may be involved in the pathogenesis of adenomyosis, we investigated and compared the occurrence of lymph vessels and lymphangiogenic growth factors in patients with adenomyosis and in those with LNG-IUD treated adenomyosis. Full thickness uterine samples from patients who underwent hysterectomy were collected and immunohistochemical statining using antibodies against podoplanin (D2-40), and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) were performed on 20 samples of adenomyosis, 20 samples of adenomyosis treated with LNG-IUD. Endometrial samples of cervical intraepithelial neoplasia served as controls. The lymphvascular density(LVD) was analyzed for each sample. Determination of LVD of the control tissue was identified by the ‘hot spot’ method. The data were evaluated using a one-way analysis of variance in combination with the Dunnett multiple comparison test and the unpaired t- test and statistical significance was defined as P <0.05. LVs were identified by immunohistochemical staining with specific lymphatic endothelial cell markers D2-40 and LYVE-1. The immunostaining patterns of all markers showed a high to moderate staining. The LVD of D2-40 and LYVE-1 were significantly higher in endometrium of adenomyosis, in comparison to the endometrium of control and LNG-IUD treated adenomyosis group. Also significant difference in LVD of endometrium was noted between the control and LNG-IUD treated adenomyosis. When the LVD was evaluated according to the menstrual cycle, no significant difference was noted between and within the group. In myometrium, the LVD was significantly higher in adenomyosis than the control and LNG-IUD treated adenomyosis group, however, no significant differences were noted between the control and LNG-IUD treated adenoymosis group. This study showed that lymphangiogenesis is increased in endometrium and myometrium of adenomyosis in comparison to the controls, and that increased LVD in adenomyosis is reduced by use of LNG-IUD. The results suggest that effect of LNG-IUD on lymphangiogenesis could be one possible mechanism of treating adenoymosis related symptoms.